Blockchain Registration Transaction Record

Immunotherapy Timing May Boost Cancer Survival, Study Finds

A systematic review in JAMA Network Open suggests earlier immunotherapy timing may improve survival in late-stage solid tumor patients. Learn how this could impact treatment protocols and companies like Calidi Biotherapeutics.

This study matters because it suggests a simple, non-invasive adjustment—timing of immunotherapy administration—could significantly improve survival for late-stage cancer patients. If validated, this could change standard treatment protocols without additional costs, potentially benefiting millions of patients globally. For investors, companies like Calidi Biotherapeutics focusing on immunotherapy may gain relevance as timing optimization becomes a key consideration in treatment efficacy.